Platelet Rich Plasma and Recurrent Implantation Failure

Not Applicable

Completed

• Conditions: Recurrent Implantation Failure

• Registration Number: NCT03996837
• Lead Sponsor: Royan Institute

Brief Summary

This study is a randomized controlled clinical trial to compare the pregnancy outcomes of infertile women with recurrent implantation failure. The study population consisted of infertile women with a history of recurrent implantation failure who had failed to achieve a clinical pregnancy which at least four good quality embryos transfers and are now candidate for IVF-ICSI or freeze embryo transfer cycles with and without intra uterine infusion of platelet rich plasma in Reproductive Biomedicine Research Center, Royan institute, Tehran Iran.

Detailed Description

Platelet Rich Plasma (PRP) is a blood product with a high platelet and a normal plasma fibrinogen level. Given the effective factors of RPR in repairing damaged tissues, its application in the field of regenerative medicine has widely been interested over the last three decades. According to the literature, PRP is an effective and safe treatment in the fields of orthopaedics, dermatology, ophthalmology, and repair of neurological, vascular, and connective tissue damage, but its application in the field of infertility is limited to a few pilot studies in which the effects of PRP on endometrium and recurrent implantation failure (RIF) were investigated. Given the importance of endometrial compliance and according to molecular studies, which indicate that endometrial growth factors in women with a history of RIF are lower than normal fertile women, PRP, along with other existing strategies, can be used to improve endometrial compliance in patients with a history of RIF. The present randomized, controlled clinical trial is proposed to determine the efficacy of PRP in the treatment of patients with RIF in the cycles of IVF-ICSI and frozen embryo transfer at Royan Institute.

Study Timeline

• Study Start: 2017-08-16
• Study First Submitted: 2019-05-26
• Study First Submitted QC: 2019-06-22
• Study First Posted: 2019-06-25
• Primary Completion: 2021-11-17
• Study Completion: 2022-05-21
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-02
• Last Update Posted: 2024-01-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

1. Infertile women with a history of recurrent implantation failure who had failed to achieve a clinical pregnancy which at least four good quality embryos transfers
2. 20<Age<40
3. 19<BMI<29
4. Non endocrine, hematologic and autoimmune disorders
5. Non chromosomal and genetic abnormalities
6. Non uterine anomalies, surgical history, endometriosis, adenomyosis, hydro salpinx, uterine fibroids, Polycystic ovary syndrome
7. Having at least three good quality embryos

Exclusion Criteria

1. Cervicitis
2. Recent fever condition
3. Use of corticosteroids (in up to 2 weeks before the procedure) or non-steroid anti-inflammatories (in up to 48 hours before procedure)
4. Anemia, thrombocytopenia, platelet dysfunction syndrome, hypofibrinogenemia
5. Septicemia, active infections with Pseudomonas, Klebsiella or Enterococcus
6. History of cancer
7. Patient's tendency for withdrawal

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Implantation rate	4-6 weeks after embryo transfer	The number of gestational sacs observed, divided by the number of embryos transferred

Secondary Outcome Measures

Name	Time	Method
Ongoing pregnancy rate	12 weeks after embryo transfer	Continued pregnancy at \> gestational week 12 or more per initiated cycle

Trial Locations

Locations (1)

Royan Institute; 🇮🇷 Tehran, Iran, Islamic Republic of